ClinicalTrials.gg
RecruitingNCT07867938Updated Nov 16, 2026

A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)

A Phase 2 interventional study of Tulisokibart and Placebo in Pulmonary Sarcoidosis, sponsored by Merck Sharp & Dohme LLC. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Updated Nov 9, 2026Now RecruitingFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Sarcoidosis, Pulmonary with a site in United States — 7 open to participants now, 8 under way, none of them phase 3. Sarcoidosis, Pulmonary · United States.

Planned enrollment
3rd of 27
158 · median 37
Started
2026
with 1 other
Phase 2
12 of 33
2 open now
Registered
33rd of 33
by date

Among the 33 studies in Sarcoidosis, Pulmonary with a site in United States, this one is the 3rd largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2026, is one of 12 in phase 2, and was the 33rd registered.

Sarcoidosis, Pulmonary

67 studies on the registry are indexed under Sarcoidosis, Pulmonary; 16 are open to participants now.

Browse Sarcoidosis, Pulmonary studies →

Open to participants now

7 of the 33 studies in Sarcoidosis, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Sarcoidosis, Pulmonary studies recruiting now, 7 (58%) set no upper age limit and 1 (8%) stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Sarcoidosis, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS).

This trial will help researchers learn if a trial medicine called tulisokibart can treat symptoms of active PS. The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until PS gets worse.

03

Conditions studied

  • Pulmonary Sarcoidosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has a diagnosis of sarcoidosis of ≥6 months before Screening confirmed by tissue
  • Has lung parenchymal involvement consistent with pulmonary sarcoidosis (PS) by chest X-ray or chest high-resolution computed tomography (HRCT) either via historical evidence or at Screening
  • Has active PS within 3 months before Screening

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a history of cancer and is disease free for \<5 years
  • Has cardiac, ocular, neurosarcoidosis, or other manifestations of sarcoidosis that requires systemic treatment that may interfere with protocol specifications, or has a abnormality that requires evaluation or intervention
  • Is receiving treatment for pulmonary hypertension
  • Has a history of fungal respiratory infection within 12 months before screening without documentation of completed treatment
  • Has a diagnosis of or currently has a clinical presentation consistent with Löfgren syndrome
  • Has active tuberculosis (TB) or history of active TB
  • Has any condition that may interfere with the ability to adhere to oral therapy or taper
  • Is a current smoker defined as smoking or vaping of inhaled preparations of nicotine, tobacco, or cannabis preparations within 6 months before Screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
158 participants (estimated)

Study arms

  • Experimental
    Tulisokibart

    Participants receive background therapy of prednisone plus tulisokibart.

    Drug: Tulisokibart · Drug: Background prednisone therapy

  • Placebo comparator
    Placebo

    Participants receive background therapy of prednisone plus placebo.

    Other: Placebo · Drug: Background prednisone therapy

Interventions

  • Subcutaneous (SC) administration

    Also known as: MK-7240, PRA023

  • OtherPlacebo

    SC administration

  • DrugBackground prednisone therapy

    Oral administration

06

What researchers measure

Primary outcomes

  1. Time to First Worsening of Pulmonary Sarcoidosis (PS)

    Worsening of PS is based on clinical judgment of worsening PS, along with pulmonary function tests and/or impaired or unacceptable loss of quality of life as measured by the King's Sarcoidosis Questionnaire (KSQ)-lung score. The time to first worsening of PS will be reported.

    Time frame: Up to approximately 52 weeks

Secondary outcomes

  1. Number of Participants Experiencing Worsening of PS

    Worsening of PS is based on clinical judgment of worsening PS, along with pulmonary function tests and/or impaired or unacceptable loss of quality of life as measured by the KSQ-lung score. The number of participants with worsening of PS will be reported.

    Time frame: Up to approximately 52 weeks

  2. Number of Participants With One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more adverse events will be reported.

    Time frame: Up to approximately 66 weeks

  3. Number of Participants Who Discontinue Study Drug Due to One or More AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study drug due to one or more AEs will be reported.

    Time frame: Up to approximately 52 weeks

07

Study locations

1 of 1 sites recruiting
  • Care Access Research Llc ( Site 2725)
    Shreveport, Louisiana 71105, United States
    Recruiting
    • Study Coordinator · Contact318-209-3290
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2026 (actual). Primary completion is estimated for Oct 2029, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2026
First posted
Oct 9, 2026
StartActual
Nov 3, 2026
Primary completionEst.
Oct 5, 2029
CompletionEst.
Jan 11, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
1 site added — first site in United States
Show site
  • Care Access Research Llc ( Site 2725) · Shreveport, United States
Nov 9, 2026
Start date
Nov 6, 2026→Nov 3, 2026 (actual)
Nov 9, 2026
Contact
Study contact now listed: added T•••@msd.com · •••8839. See the current contact
Nov 9, 2026
Registered
First appeared on the registry
Oct 9, 2026
Show all 3 updates
  1. Nov 16, 2026
    Minor edits only
    + 1 other change: references
  2. Nov 9, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Care Access Research Llc ( Site 2725) · Shreveport, United States
    Start date Nov 6, 2026→Nov 3, 2026 (now actual)
    Contact Study contact now listed: added T•••@msd.com · •••8839. See the current contact
    + 1 other change: verification date
  3. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07867938
Responsible party
Sponsor
First posted
Oct 9, 2026
Start date
Nov 3, 2026
Primary completion
Oct 5, 2029 (estimated)
Completion
Jan 11, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tulisokibart

Start the discussion